GlobeNewswire Inc. · Jan 6, 2023
Nabriva Therapeutics Provides Corporate Update
-Company To Focus on Preserving Cash to Fund Orderly Wind Down of Operations-
NB
NASDAQ · NBRV
Nabriva Therapeutics plc
Healthcare · Biotechnology
$1.42
Up+$0.01 (+0.71%)
Updated Sep 16, 2026, 11:06 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 4.55M
- P/E ratio
- -0
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 706.54K
- Avg. volume
- 27.4K
Price performance
NBRV price history
1M range · 0 trading sessions · Daily adjusted prices
NBRV does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest NBRV news
The latest Smart Investors Daily articles mentioning NBRV.
Stock researchCompany · Overview
NBRV research
Overview
Company profile and research snapshot.
Company profile
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $1.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 16, 2022 | Northland Capital Markets | Outperform | — |
| Mar 30, 2022 | Northland Capital Markets | Outperform | — |
| Dec 7, 2020 | Morgan Stanley | Equal-Weight | — |
| Apr 9, 2020 | H.C. Wainwright | Neutral | — |
| Apr 9, 2020 | HC Wainwright & Co. | Neutral | — |
News briefing
No generated briefing is available yet.
Zacks Investment Research · Nov 29, 2022
Nabriva (NBRV) Posts Positive Data From Cystic Fibrosis Study
Nabriva (NBRV) posts positive top-line data from the phase I study evaluating oral and intravenous Xenleta (lefamulin) in adult patients with cystic fibrosis. Shares down.
GlobeNewswire Inc. · Nov 28, 2022
Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis
- PK Data and Safety Profile Consistent with Previous Studies in Healthy Subjects –
GlobeNewswire Inc. · Nov 10, 2022
Nabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate Update
- Shifted Focus to SIVEXTRO to Enable Cost Cutting -
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
